Completed PHASE3 INTERVENTIONAL NCT00125892

A Study of Duloxetine in the Treatment of Fibromyalgia

A 1-Year Safety Study of Duloxetine in Patients With Fibromyalgia Syndrome

Sponsor: Boehringer Ingelheim

Interventions duloxetine

Updated 7 times since 2017 Last updated: May 16, 2007 Started: Jul 31, 2005 Completion: Mar 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Fibromyalgia and is currently completed. Boehringer Ingelheim leads this study, which shows 7 recorded versions since 2005 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE3
Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jul 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Boehringer Ingelheim
Eli Lilly and Company

Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Buenos Aires, Argentina , Capital Federal, Argentina , Cotton Tree, Australia , Curitiba, Brazil , Goiânia, Brazil , Guadalajara, Mexico , Hobart, Australia , Kaohsiung City, Taiwan , London, Canada , Lublin, Poland and 17 more locations